Scarica l'app Stockscreener
13.14
1.72%
-0.23
Dopo l'orario di chiusura:
13.24
0.10
+0.76%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - Yahoo Finance
Tonix CEO will speak at a healthcare conference Sept. 10 - Stock Titan
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock - MarketBeat
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock - Investing.com
Tonix Pharma (NASDAQ: TNXP) CEO adds 2,000 shares in IRA - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada
Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock - MarketBeat
Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingPositive Gamma - siam.in
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript - AOL.com
Tonix (TNXP) Daily Snapshot: Finishes 0.16% Higher at $12.68 in Latest Trading; the $12.05 to $13.31 Range Remains in Focus under the Current SnapshotValue Area High - Vinanet
Why TNXP Stock Is Suddenly Back On Retail Radar - stocktwits.com
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline - MarketBeat
Tonix Pharmaceuticals (TNXP) Holds Ground at $12.66 as Traders Eye $13.29 ResistanceTrend Reversal Picks - vinanet.vn
Tonix Pharmaceuticals Holding Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNXP) 2026-08-14 - Seeking Alpha
Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants - Stock Titan
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan
TNXP Q2 2026 Earnings: Better-Than-Expected Loss per Share, Shares Dip 3%Guidance Accuracy Score - Vinanet
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Tonix Pharmaceuticals Holding Corp.Common Stock (NQ: TNXP - FinancialContent
Industry Analysts Just Made A Dazzling Upgrade To Their Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Revenue Forecasts - Moomoo
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance UK
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build By Investing.com - Investing.com UK
Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns - simplywall.st
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build - Investing.com India
Tonix Pharmaceuticals: TONMYA Refills Surge 207% As Coverage Reaches 136 Million U.S. Lives - Pulse 2.0
Tonix Pharma earnings beat by $0.27, revenue topped estimates - Investing.com Nigeria
Tonix Delivers A Beat, But The Real Test Starts Now (NASDAQ:TNXP) - Seeking Alpha
Raymond James raises Tonix Pharma stock price target on strong sales - Investing.com UK
Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal? - Kalkine Media
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Cal - GuruFocus
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... - Yahoo Finance UK
Tonix Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
TNXP: Tonmya's launch fueled major Q2 revenue growth and pipeline progress, with cash runway into 2027 - TradingView
Earnings call transcript: Tonix beats Q2 2026 estimates as TONMYA sales surge - Investing.com Nigeria
Tonix Pharmaceuticals Holding Releases Q2 2026 Financial Results - AlphaStreet
TNXP: TONMYA sales nearly tripled in Q2 2026, driving revenue growth and supporting robust pipeline progress - TradingView
Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results - MarketBeat
TNXP: Q2 2026 net revenue reached $13.5M, driven by TONMYA's 197% QoQ sales growth - tradingview.com
Q2 2026 Tonix Pharmaceuticals Holding Corp Earnings Call Transcript - GuruFocus
Is Tonix Pharmaceuticals (TNXP) Overvalued After Q2 Earnings Rep - GuruFocus
TNXP Looks 584.3% Overvalued on GF Value™ - GuruFocus
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):